Insider Selling: Medpace (NASDAQ:MEDP) VP Sells $2,667,380.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 3,940 shares of the business’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $677.00, for a total value of $2,667,380.00. Following the transaction, the vice president owned 54,012 shares of the company’s stock, valued at approximately $36,566,124. The trade was a 6.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Stock Down 3.8%

Shares of NASDAQ:MEDP opened at $652.01 on Friday. The business’s 50 day moving average is $619.12 and its 200 day moving average is $531.32. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $693.97. The stock has a market cap of $18.24 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 2.63 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.40. The company had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. Medpace’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.86 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 18.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the second quarter valued at approximately $27,000. Jones Financial Companies Lllp purchased a new stake in Medpace during the 2nd quarter valued at approximately $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace during the 2nd quarter valued at approximately $31,000. Kilter Group LLC bought a new stake in Medpace in the second quarter worth $31,000. Finally, Basecamp Wealth Advisors LLC lifted its position in shares of Medpace by 187.5% during the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MEDP shares. Robert W. Baird set a $699.00 price target on shares of Medpace in a research note on Friday, October 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. UBS Group raised their price target on shares of Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Weiss Ratings raised shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Royal Bank Of Canada increased their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $649.27.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.